Rhythm Pharmaceuticals
RYTM
285 hedge funds and large institutions have $6.42B invested in Rhythm Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 101 increasing their positions, 89 reducing their positions, and 51 closing their positions.
776% more call options, than puts
Call options by funds: $16.4M | Put options by funds: $1.87M
25% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 51
13% more repeat investments, than reductions
Existing positions increased: 101 | Existing positions reduced: 89
2% more funds holding
Funds holding: 279 → 285 (+6)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
1.43% less ownership
Funds ownership: 109.17% → 107.74% (-1.4%)
18% less capital invested
Capital invested by funds: $7.8B → $6.42B (-$1.38B)
Top Buyers
Top Sellers
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$311M |
| 2 |
Jennison Associates
New York
|
-$98.3M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$82.5M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$32.8M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$26.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CWMS
326
CFG Wealth Management Services
Indianapolis,
Indiana
| – | -$85.6K | -800 | Closed |
|
327
Daiwa Securities Group
Tokyo,
Japan
| – | -$22K | -201 | Closed |
|
|
AF
328
Advisornet Financial
Minnetonka,
Minnesota
| – | -$14.7K | -137 | Closed |
|
|
BC
329
Bayforest Capital
London,
United Kingdom
| – | -$14.3K | -134 | Closed |
|
|
QL
330
Quarry LP
New York
| – | -$8.24K | -77 | Closed |
|
|
RS
331
Rakuten Securities
Tokyo,
Japan
| – | -$1.61K | -15 | Closed |
|
|
SIC
332
SJS Investment Consulting
Sylvania,
Ohio
| – | -$215 | -2 | Closed |
|
|
DF
333
Dunhill Financial
London,
United Kingdom
| – | -$65 | -1 | Closed |
|
|
RWM
334
Rialto Wealth Management
Syracuse,
New York
| – | -$108 | -1 | Closed |
|
|
TPCW
335
TD Private Client Wealth
New York
| – | -$107 | -1 | Closed |
|
RYTM Hedge Fund Activity: Q1 2026 in Review
285 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2026, worth a combined $6.42B — down 18% from $7.8B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new RYTM positions and 51 closed out — a net gain of 13 holders — while 101 added to existing stakes and 89 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $123M. The largest seller was NEA Management Company, exiting entirely with an estimated $311M sold.
- 285 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2026, up from 279 in Q4 2025.
- Funds reported $6.42B of Rhythm Pharmaceuticals stock for Q1 2026, down 18% quarter-over-quarter.
- 64 funds opened new Rhythm Pharmaceuticals positions in Q1 2026 and 51 closed out, a net change of +13 holders.
- The largest Rhythm Pharmaceuticals buyer in Q1 2026 was Citadel Advisors, an estimated $123M added.
- The largest Rhythm Pharmaceuticals seller in Q1 2026 was NEA Management Company, an estimated $311M sold.
Based on aggregated 13F filings for Q1 2026.